Novo A/S - GlyProVas - Bacterial glycoprotein antigens for vaccine development

Projekter: ProjektForskning



Recent work has revealed that protein glycosylation in pathogenic bacteria such as E. coli, Campylobacter jejuni, Mycobacterium tuberculosis and Helicobacter pylori play an important role in mediating infection1. Bacteria make use of distinct monosaccharide building blocks which are absent from human and animal cells, and therefore foreign to the human immune system. Thus, glycoproteins constitute a distinguishing feature of bacteria which can provide attractive targets for antimicrobial intervention for example in the form of vaccines. While the intimate coupling between protein glycosylation and bacterial pathophysiology has been documented, the discovery of novel glycoproteins implicated in virulence is only advancing slowly. For example, the known protein glycosylation repertoire of pathogenic E. coli is limited to just four proteins. This gap of knowledge in bacteria is linked to the technical challenges of identifying glycoproteins in bacteria.
Effektiv start/slut dato01/03/201528/02/2017